D. Bafaloukos

1.0k total citations
37 papers, 777 citations indexed

About

D. Bafaloukos is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, D. Bafaloukos has authored 37 papers receiving a total of 777 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in D. Bafaloukos's work include Cancer Treatment and Pharmacology (13 papers), Colorectal Cancer Treatments and Studies (9 papers) and Lung Cancer Treatments and Mutations (6 papers). D. Bafaloukos is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), Colorectal Cancer Treatments and Studies (9 papers) and Lung Cancer Treatments and Mutations (6 papers). D. Bafaloukos collaborates with scholars based in Greece, Australia and United Kingdom. D. Bafaloukos's co-authors include Evangelos Briasoulis, C. Papadimitriou, Helena Linardou, Sharon C. Murray, George Fountzilas, P. Kosmidis, Nicholas Pavlidis, Haralabos P. Kalofonos, E. Samantas and Dimosthenis Skarlos and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

D. Bafaloukos

34 papers receiving 759 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. Bafaloukos Greece 13 566 191 185 176 136 37 777
Karwan Moutasim United Kingdom 17 455 0.8× 440 2.3× 193 1.0× 67 0.4× 100 0.7× 35 1.0k
Kei Ijichi Japan 16 528 0.9× 189 1.0× 98 0.5× 143 0.8× 118 0.9× 41 802
J. L. Abbruzzese United States 17 636 1.1× 309 1.6× 174 0.9× 98 0.6× 26 0.2× 51 905
Nagaaki Terakado Japan 18 420 0.7× 313 1.6× 149 0.8× 37 0.2× 88 0.6× 30 872
Mark S. Rubin United States 8 336 0.6× 143 0.7× 100 0.5× 167 0.9× 107 0.8× 14 492
N J Agnantis Greece 13 223 0.4× 169 0.9× 69 0.4× 82 0.5× 46 0.3× 24 429
Yasutaka Hayashido Japan 17 269 0.5× 344 1.8× 49 0.3× 65 0.4× 87 0.6× 47 780
C. Bumma Italy 16 546 1.0× 122 0.6× 186 1.0× 87 0.5× 57 0.4× 52 806
Philip T. Cagle United States 10 332 0.6× 287 1.5× 352 1.9× 83 0.5× 33 0.2× 12 828
Izumi Yoshitomi Japan 14 323 0.6× 253 1.3× 80 0.4× 40 0.2× 55 0.4× 30 584

Countries citing papers authored by D. Bafaloukos

Since Specialization
Citations

This map shows the geographic impact of D. Bafaloukos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Bafaloukos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Bafaloukos more than expected).

Fields of papers citing papers by D. Bafaloukos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Bafaloukos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Bafaloukos. The network helps show where D. Bafaloukos may publish in the future.

Co-authorship network of co-authors of D. Bafaloukos

This figure shows the co-authorship network connecting the top 25 collaborators of D. Bafaloukos. A scholar is included among the top collaborators of D. Bafaloukos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Bafaloukos. D. Bafaloukos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Koutras, Αngelos, Vassiliki Kotoula, G. Kouvatseas, et al.. (2016). Evaluation of the association of HER family members with efficacy of trastuzumab therapy in metastatic breast cancer. Annals of Oncology. 27. vi32–vi32. 1 indexed citations
3.
Murray, Sharon C., Evangelos Briasoulis, Helena Linardou, D. Bafaloukos, & C. Papadimitriou. (2012). Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies. Cancer Treatment Reviews. 38(7). 890–903. 214 indexed citations
4.
Mauri, Davide, George Pentheroudakis, D. Bafaloukos, et al.. (2006). Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data.. PubMed. 26(4B). 3175–81. 43 indexed citations
5.
6.
Bafaloukos, D., Dimosthenis Tsoutsos, Haralabos P. Kalofonos, et al.. (2004). Temozolomide and cisplatin (TP) vs temozolomide (T) in patients with advanced melanoma. A randomized phase II of the Hellenic Cooperative Oncology Group. Journal of Clinical Oncology. 22(14_suppl). 7545–7545. 1 indexed citations
7.
Papadiamantis, J., et al.. (2004). The effect of exemestane on the lipidemic profile of breast cancer patients: Preliminary results of the TEAM trial Greek sub-study. Journal of Clinical Oncology. 22(14_suppl). 799–799. 2 indexed citations
8.
Markopoulos, Christos, et al.. (2004). The effect of exemestane on the lipidemic profile of breast cancer patients: Preliminary results of the TEAM trial Greek sub-study. Journal of Clinical Oncology. 22(14_suppl). 799–799. 6 indexed citations
9.
Kalofonos, Haralabos P., D. Skarlos, D. Bafaloukos, et al.. (2003). A Phase II Study with CPT-11 Plus Leucovorin and Bolus IV 5-Fluorouracil in Patients with Advanced Colorectal Carcinoma. Cancer Investigation. 21(6). 855–862. 7 indexed citations
10.
Panagiotou, Irene, et al.. (2002). Malignant melanoma metastatic to the gastrointestinal tract. Melanoma Research. 12(2). 169–173. 36 indexed citations
11.
Fountzilas, George, D. Tsavdaridis, Anna Kalogera‐Fountzila, et al.. (2001). Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. Annals of Oncology. 12(11). 1545–1551. 61 indexed citations
12.
Razis, Evangelia, Meletios Α. Dimopoulos, D. Bafaloukos, et al.. (2001). Dose-Dense Sequentials Chemotherapy with Epirubicin and Paclitaxel in Advanced Breast Cancer. Cancer Investigation. 19(2). 137–144. 6 indexed citations
13.
Pectasides, D., Gerasimos Aravantinos, Haralabos P. Kalofonos, et al.. (2001). Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology. 12(10). 1417–1422. 28 indexed citations
14.
Briasoulis, Evangelos, Maria Tsokos, George Fountzilas, et al.. (1998). Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study.. PubMed. 18(3B). 1907–14. 44 indexed citations
15.
Briasoulis, Evangelos, George Fountzilas, Athanasios Athanasiadis, et al.. (1998). Combination Regimen with Carboplatin, Epirubicin and Etoposide in Metastatic Carcinomas of Unknown Primary Site: A Hellenic Co-Operative Oncology Group Phase II Study. Oncology. 55(5). 426–430. 21 indexed citations
16.
17.
Pavlidis, Nicholas, P. Kosmidis, Dimosthenis Skarlos, et al.. (1992). Original article: Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site. Annals of Oncology. 3(8). 631–634. 24 indexed citations
18.
Bafaloukos, D., et al.. (1989). First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer. British Journal of Cancer. 60(5). 755–758. 4 indexed citations
19.
Pectasides, Dimitrios, et al.. (1989). Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin. British Journal of Cancer. 60(4). 627–629. 23 indexed citations
20.
Athanassiou, A., et al.. (1988). Successful Chemotherapy for Disseminated Testicular Sertoli Cell Tumour. British Journal of Urology. 61(5). 456–457. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karwan Moutasim Breakdown of academic impact, for papers by Kei Ijichi Breakdown of academic impact, for papers by J. L. Abbruzzese Breakdown of academic impact, for papers by Nagaaki Terakado Breakdown of academic impact, for papers by Mark S. Rubin Breakdown of academic impact, for papers by N J Agnantis Breakdown of academic impact, for papers by Yasutaka Hayashido Breakdown of academic impact, for papers by C. Bumma Breakdown of academic impact, for papers by Philip T. Cagle Breakdown of academic impact, for papers by Izumi Yoshitomi
Rankless by CCL
2026